Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis
Introduction: Lung cancer is the leading cause of cancer-related deaths worldwide, and non-small cell lung carcinoma (NSCLC) accounts for approximately 80% of all cases. Immune checkpoint inhibitors (ICIs) are widely used to treat NSCLC owing to their remarkable efficacy. In this study, we analyzed...
Saved in:
Main Authors: | Yue Zhang (Author), Lishan Lu (Author), Rui Zheng (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
by: Yantao Xu, et al.
Published: (2022) -
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023) -
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023) -
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
by: Zhangfeng Huang, et al.
Published: (2020) -
Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
by: Liyan Zhang, et al.
Published: (2021)